Market Cap (In KRW)
1276.47 Billion
Revenue (In KRW)
-
Net Income (In KRW)
-36.84 Billion
Avg. Volume
383 Thousand
- Currency
- KRW
- Country
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 28350.0-125900.0
- PE
- -
- EPS
- -
- Beta Value
- 1.828
- ISIN
- -
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Industry
- CEO
- Sunghwan Kim Ph.D.
- Employee Count
- -
- Website
- https://voronoi.io
- Ipo Date
- 2022-06-24
- Details
- Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
More Stocks
-
007460Aprogen Medicines Inc.
007460
-
019685Daekyo Co., Ltd.
019685
-
LH-R
-
001275BOOKOOK Securities Co., Ltd.
001275
-
1611
-
1585
-
HERBYaSheng Group
HERB
-
TCPC